SOUTH SAN FRANCISCO, Calif., May 6, 2024 (Globe Newswire) — Allogene Therapeutics, Inc. (Nasdaq: ALLO) is committed to developing allogeneic CAR T (AlloCAR T™) products against cancer and cancer. A pioneering clinical-stage biotechnology company. Autoimmune Disease announced today that it will report its first quarter 2024 financial results and provide a business update on May 13, 2024 after the market closes. The announcement will be followed by a live audio webcast and conference call starting at 2:00 PM PT/5:00 PM ET.
Listen-only webcast
This listening-only webcast will be available on the “Investors” tab in the “News and Events” section of our website www.allogene.com. Rebroadcasts will be available for viewing on our website for approximately 30 days.
Conference Call Registration
If you would like the option to ask questions via conference call, please register using this link. Once you register for the conference call, you will receive a personal PIN to access the call.
About Allogene Therapeutics
Allogene Therapeutics, headquartered in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune diseases. Led by a management team with extensive experience in cell therapy, Allogene aims to deliver readily available cell therapies on demand, more reliably, and at scale, with the aim of delivering “off-the-shelf” his CAR T cells. We are developing a pipeline of product candidates. To more patients. For more information, visit www.allogene.com and follow @AllogeneTx on X (formerly Twitter) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements About Allogeneic
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among other things, statements regarding intentions, beliefs, projections, prospects, analyzes or current expectations regarding Allogene. the ability to develop readily available allogeneic CAR T products for the treatment of cancer and autoimmune diseases and deliver them on demand, more reliably and at scale to more patients; Various factors could cause material differences between Allogene’s expectations and actual results. These include the risks and uncertainties associated with our product candidates because they are based on new technology, the time and cost of developing our product candidates, and the difficulty in predicting the safety or effectiveness of our products. Masu. whether our product candidates receive regulatory approval; This may prevent or delay commercialization. These and other risks are described in Allogene’s SEC filings, including, without limitation, under the heading “Risk Factors” in its Annual Report on Form 10-K filed for the year ended December 31, 2023. is explained in detail. The information contained in this press release speaks only as of the date of this press release. Allogene undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Executive Officer and Head of Brand Strategy
Christine.Cassiano@allogene.com
